STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV
RHGH A/O 罗格列酮治疗 HIV 的安全性和有效性研究
基本信息
- 批准号:7378403
- 负责人:
- 金额:$ 26.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-01 至 2007-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: that (1) co-administration of rosiglitazone with recombinant human growth hormone (rhGH) will abrogate the adverse effect of rhGH on insulin sensitivity that may be mediated by increased free fatty acid (FFA) turnover and will have a synergistic effect on reducing visceral adiposity; and (2) the effects of rosiglitazone and rhGH on subcutaneous adipose tissue volume will be determined by their effects on total energy balance. Primary Objectives: to determine (1) the individual and interacting effects of rosiglitazone and rhGH on insulin sensitivity, as assessed by frequently sampled intravenous glucose tolerance test, in HIV-infected subjects with visceral adiposity and insulin resistance; and (2) the individual and interacting effects of rosiglitazone and rhGH on body composition assessed by whole body MRI and dual energy X-ray absorptiometry (DEXA) in HIV-infected subjects with visceral adiposity and insulin resistance.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。假设:(1)罗格列酮与重组人生长激素(rhGH)联合给药将消除rhGH对胰岛素敏感性的不良影响(可能由游离脂肪酸(FFA)周转增加介导),并对减少内脏肥胖具有协同作用;(2)罗格列酮和rhGH对皮下脂肪组织体积的影响将通过其对总能量平衡的影响来确定。主要目的:确定(1)罗格列酮和rhGH对内脏肥胖和胰岛素抵抗的HIV感染受试者胰岛素敏感性的个体和相互作用效应,通过频繁采样的静脉葡萄糖耐量试验进行评估;和(2)罗格列酮和rhGH对HIV-1患者全身MRI和双能X线吸收测定法(DEXA)评估的身体组成的个体和相互作用。内脏肥胖和胰岛素抵抗的受感染者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARSHALL J GLESBY其他文献
MARSHALL J GLESBY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARSHALL J GLESBY', 18)}}的其他基金
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
- 批准号:
10509159 - 财政年份:2021
- 资助金额:
$ 26.26万 - 项目类别:
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
- 批准号:
10703241 - 财政年份:2021
- 资助金额:
$ 26.26万 - 项目类别:
1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
1/2 强力霉素治疗艾滋病毒感染者肺气肿:DEPTH 试验
- 批准号:
10259295 - 财政年份:2021
- 资助金额:
$ 26.26万 - 项目类别:
Doxycycline for COPD in HIV-Infected Patients
多西环素治疗 HIV 感染者的慢性阻塞性肺病
- 批准号:
8445031 - 财政年份:2012
- 资助金额:
$ 26.26万 - 项目类别:
Doxycycline for COPD in HIV-Infected Patients
多西环素治疗 HIV 感染者的慢性阻塞性肺病
- 批准号:
8554373 - 财政年份:2012
- 资助金额:
$ 26.26万 - 项目类别:
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 26.26万 - 项目类别:
Investigating the efficacy and safety profiles of Bimekizumab in treating moderate-to-severe plaque psoriasis: A Canadian retrospective study
调查 Bimekizumab 治疗中重度斑块状银屑病的疗效和安全性:加拿大回顾性研究
- 批准号:
484723 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
Studentship Programs
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
一项 2 期、随机、双盲、4 组、多中心研究,旨在证明处方药局部剂量制剂治疗光化性角化病的有效性和安全性
- 批准号:
10820810 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device
使用皮肤喷雾装置治疗隐性营养不良性大疱性表皮松解症的 iPS 细胞疗法的安全性、耐受性和有效性研究
- 批准号:
10721324 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
评估联合系统化疗和多轮内镜超声引导射频消融治疗胰腺癌的安全性和有效性的单组 II 期研究
- 批准号:
10743356 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."
“第一阶段研究的安全性
- 批准号:
10730723 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022)
一项 2 期研究,调查 EXT608 在成人甲状旁腺功能减退症中的安全性、耐受性和有效性(IND146180;2022 年 10 月 14 日)
- 批准号:
10862054 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
REM-001 光动力疗法 (PDT) 治疗皮肤转移性乳腺癌 (CMBC) 的开放标记单臂 2 期疗效和安全性研究
- 批准号:
10699535 - 财政年份:2023
- 资助金额:
$ 26.26万 - 项目类别:
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
CoVPN 3003 评估 Ad26.COV2.S 在 18 岁及以上成年人中预防 SARS-CoV-2 介导的 COVID-19 的功效和安全性的 3 期研究 LC 3
- 批准号:
10570748 - 财政年份:2022
- 资助金额:
$ 26.26万 - 项目类别:
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
- 批准号:
10681470 - 财政年份:2022
- 资助金额:
$ 26.26万 - 项目类别:














{{item.name}}会员




